News | September 21, 2008

3D Conformal RT Shortens Treatment Time, Study Says

September 22, 2008 - Women with early stage breast cancer who choose lumpectomy and radiation as their treatment option may be able to significantly shorten their total treatment time using three-dimensional conformal radiation therapy (3DCRT) according to new research from the Radiation Therapy Oncology Group (RTOG) presented at ASTRO 2008.

RTOG, an NCI-funded national clinical trials group, is a clinical research component of the American College of Radiology (ACR).

Breast conserving therapy of lumpectomy followed by radiotherapy, with its superior cosmetic result and equivalent survival outcome, is an accepted option instead of mastectomy for many patients with stage I or II breast cancer. A major drawback of standard breast conserving therapy is that it is a more complicated treatment regimen requiring five to seven weeks to complete radiotherapy. Using 3DCRT to more accurately target the radiation and spare uninvolved areas of the breast, RTOG researchers are able to deliver radiation to the tumor bed site in higher doses more quickly thus shortening the post lumpectomy treatment time to one week.

“These are very preliminary but encouraging results for women who need treatment but who also have families, careers and other factors to consider when deciding on breast conservation therapy for cancer," said Frank Vicini, M.D., chief of oncology, Beaumont Hospitals, Royal Oak, Mich. “We are leading a large, National Cancer Institute-sponsored clinical trial to give us more information on the benefits vs. risks of accelerated breast irradiation in one week compared to standard radiation therapy for up to seven weeks.”

The phase II study, RTOG 0319, enrolled 58 women from 24 academic and community institutions in the U.S. and Canada from August 2003 until April 2004. The women enrolled on the study received 3DCRT twice daily, with each dose separated by six hours, for five consecutive days. Fifty-three of the patients were evaluable for efficacy reporting with a median follow-up of 4.0 years. At four years the disease-free survival rate was 84 percent, mastectomy-free survival was 90 percent, and overall survival was 96 percent. This is comparable to published rates for standard therapy.

“RTOG is able to test innovative treatment options such as accelerated partial breast irradiation with 3DCRT in a wide variety of treatment facilities both in the community and in academic centers. This allows us to respond to the needs of community physicians and moves proven, new therapies into general practice faster,” said Walter J. Curran, Jr., the RTOG Group Chair, and the Lawrence W. Davis Professor and chair of the department of radiation oncology in the Emory School of Medicine and chief medical officer of the Emory Winship Cancer Institute.

For more information: www.rtog.org, www.acr.org

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init